This site is intended only for healthcare professionals resident in the United Kingdom

Information relating to specific disease areas aligned to Pfizer’s portfolio and other resources designed for Pfizer medicines.

See all Therapy areas

Champix® (varenicline tartrate) Prescribing Information.  Adverse event reporting information can be found at the bottom of the page.

The Champix 4 week initiation pack

Patients should be treated with Champix for 12 weeks.  We understand that the first few weeks are the hardest when trying to quit smoking.1-3 That's why we have a 4-week initiation pack, to help get your patients through this challenging time.​​​​​​​

The first month is the hardest when trying to quit smoking.  Below is an example time course of withdrawal symptoms and cravings:

Cravings and withdrawal symptoms

Cravings and withdrawal symptoms often peak in the first week but can continue for some time.1-3 The 4-week initiation pack ensures that your patients have treatment available to take them through the first 2 weeks of their quit attempt.4

2-week Initiation Pack: Covers patients for at most the first 6 days of their quit attempt, depending on their start date (8-14 days before their quit date)1

4-week Initiation Pack: Can help them to get through the first few weeks when they are most vulnerable, to help make quitting less challenging.

The longer a patient stays on their 12-week course of treatment, the more likely they are to succeed:

UK study in patients receiving Champix

  • A UK study in patients receiving Champix showed that:5​​​​​​​​​​​​​​
    • Completing a 12-week course results in an 11-fold increase in the chance of a successful quit attempt compared to those who receive up to 2 weeks of treatment.

The Champix 4-week pack can help address some of the key reasons for non-compliance:*6,7​​​​​​​

  • Clearly labelled initiation pack helps to aid compliance8
  • Gives patients more time to schedule an appointment for their repeat prescription which reduces risk of patient running out of treatment and may reduce treatment discontinuations6
  • ​​​​​​​Reduces prescription costs for patients compared with using 2-week initiation and continuation packs.
  • Fewer GP visits for repeat prescriptions needed with the 4-week pack which is more convenient for patients and saves GP's time and practice resources.

*Key reasons for non-adherence for general medicines from a patient survey 20027

Make quitting less challenging with a simplified prescription schedule:

Together with appropriate behavioural support, the Champix 4-week pack can help get patients through those challenging first few weeks and stay on treatment for longer.6

2-Week and 4-Week Schedule Example:


References:
  1. Hughes JR. Nicotine Tob Res 2007;9(3):315—327.
  2. O’Connell KA et al. Res Nurs Health 1998 Dec;21(6):487—497.
  3. West R, Schiffman S. Fast Facts: Smoking Cessation, Second Edition, June 2007.
  4. Champix Summary of Product Characteristics http://www.medicines.org.uk/emc/medicine/19045
  5. Blak BT et al. Curr Med Res Opin 2010;26:(4):861—870.
  6. Pfizer Data on File
  7. BCG. Focus, December 2003.
  8. Healthcare Compliance Packaging Council, White Paper. Improving Medication Adherence with Packaging
PP-CHM-GBR-3365. June 2021

Champix efficacy vs NRT

Read about how Champix compares to nicotine replacement therapies.

Champix efficacy data

Resources for you

Learn more about how using Very Brief Advice (VBA) and Brief Support and Treatment (BST) can help a smoker gain the motivation and support needed, to quit successfully.

Learn more

Quick Links

For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-2688. December 2020

Yes

No